

03 May 2018 | News

QUOTED. May 3, 2018. Patricia Zilliox.

by

See what ophthalmic industry veteran and Eyevensys CEO Patricia Zilliox said about the opportunity for her firm's technology to target eye diseases at this year's BioTrinity 2018 in London.

"I've been working in ophthalmology for 25 years and looking for a technology like this. Everything has been tried, and I've worked on everything, so when I saw this project, I thought this technology was a complete game changer, as we're using the ciliary muscle in the eye as a factory to manufacture proteins on an ongoing basis." – Patricia Zilliox, CEO, Eyevensys

- Find out more: [BioTrinity 2018: Bullish M&A And IPO Outlook; Spotlight On Eyevensys, Rexgenero](#)

[Click here](#) for a free trial of *Medtech Insight*